Table 1. Characteristics of the included studies.

Study	Time frame	Country	Age (years)a	Total patients (N)	Grade (n)				Surgery		Median follow-up time (months)	Ref.
					Benign	Borderline	Malignant		BCS	M
Mangi 1999	1980–1997	USA	41.3	40	34	3	3		31	9	43.01	(6)
Chaney 2000	1944–1998	USA	41	101	59	12	30		47	54	47	(20)
Kapiris 2001	1947–1999	UK	47	48	0	0	48		24	24	108	(7)
Sotheran 2005	1982–2000	UK	n/a	50	29	12	9		46	4	35	(21)
Tan 2005	1992–2002	Singapore	42	335	250	54	31		311	23	20.4	(22)
Chen 2005	1985–2003	China	37	172	131	12	29		126	46	71	(8)
Abdalla 2006	n/a	Egypt	42	79	31	27	21		46	33	60	(9)
Akin 2010	1998–2002	Turkey	45.5	10	7	0	3		7	3	62	(23)
Jung 2010	1998–2006	Korea	37.6	67	39	16	12		61	5	n/a	(24)
Jang 2012	1995–2009	Korea	43	164	82	42	40		148	16	33.6	(13)
Tsang 2012	n/a	China	45	185	120	48	17		n/a	n/a	42	(25)
Kim 2013	2000–2010	South Korea	41	193	145	33	15		182	11	65	(12)
Spitaleri 2013	1999–2010	Italy	44	172	68	42	62		137	35	85	(26)
Wei 2014	1997–2012	China	40	192	80	63	49		145	47	72.9	(27)
Onkendi 2014	1971–2008	USA	47	67	0	15	52		32	35	120	(28)
Yom 2015	1989–2008	Korea	36.44	285	191	61	33		271	14	81.4	(29)
Bellezza 2016	1988–2009	Italy	42	62	40	13	9		53	9	n/a	(30)
Borhani-Khomani 2016	1999–2014	Denmark	45.6	443	354	89	0		395	10	98	(15)
Moutte 2016	2003–2013	France	37.9	76	67	9	0		75	1	58	(31)
Ruvalcaba-Limón 2016	2005–2015	Mexico	41.7	305	222	50	35		213	92	36.2	(32)
Moo 2017	2003–2013	USA	35	246	216	30	0		243	3	35.5	(33)
Rodrigues 2017	1999–2014	The Netherlands	48	183	83	50	49		163	19	65	(34)
Tremblay-LeMay 2017	1998–2010	Canada	44.4	114	81	20	13		112	2	15.48/59.88/65.04b	(35)
Chng 2018	2006–2015	Singapore	37.7	240	196	27	17		n/a	n/a	19.2	(36)
Choi 2018	1981–2014	Korea	43	362	0	127	235		247	84	60	(37)
Sevinc 2018	1994–2017	Turkey	40.6	122	14	0	122		n/a	n/a	39	(38)
Mitus 2018	1952–2013	Poland	51	334	187	40	107		248	86	121	(39)
Zhou 2018	2002–2013	China	41	404	168	184	52		378	26	46	(40)
Gulben 2019	2008–2014	Turkey	34	89	68	14	7		85	4	n/a	(41)
Li 2019	1999–2009	China	43.2	290	181	76	33		233	36	n/a	(42)
Wen 2020	2008–2017	Canada	43	96	75	10	11		88	8	47.3	(43)
Genco 2021	2005–2019	USA	36	205	191	14	0		n/a	n/a	n/a	(44)
Lim 2021	2002–2014	Canada	45.8	150	110	21	19		120	30	36	(45)
Rosenberger 2021	2007–2017	USA	44	550	379	108	58		512	34	36.7	(18)

^a, age is represented by the average or the median age of the study. ^b, the median follow-up time was 15.48 months for benign, 59.88 months for borderline, and 65.05 months for malignant PTs. BCS, breast conservative surgery; M, mastectomy; n/a, not available; PTs, phyllodes tumors.